NEW YORK (GenomeWeb News) – Affymetrix has filed its CytoScan cytogenetics platform with the US Food and Drug Administration, a company official said at the Leerink Swann Global Healthcare Conference yesterday.

"We have ... completed the CytoScan filing with the FDA," Affy CFO Tim Barabe said at the conference. "So it's in the works, it's with them.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.